Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
GLP-1 Agonists Market: By Route of Administration, By Molecule, By Distribution Channel, and Geography
GLP-1 Agonists Market was valued at US$ 21,867.6 million in 2022 and is poised to grow at a CAGR of 17.9% over 2024-2030. Glucagon-like peptide-1 (GLP-1) agonists are a type of medication that is mostly used to treat type 2 diabetes. These medications replicate the activity of endogenous GLP-1, a hormone that is essential for glucose regulation. The market for GLP-1 Agonists is experiencing significant growth owing to the increase in the number of people suffering from Type 2 diabetes. Currently, GLP-1 agonist molecules are also prescribed off-label for obesity conditions. For instance, according to the National Diabetes Statistics Report, released by CDC about 38.4 million people have diabetes i.e., about 11.6% of the US population suffer from diabetes. Globally more than 537 million people are having diabetes conditions, and 764 million people are living with obesity.
The market for glucagon-like peptide-1 (GLP-1) agonists has seen tremendous development and transition, driven by a variety of factors that affect its direction. The documented efficacy in diabetes management and the considerable cardiovascular advantages associated with particular GLP-1 agonists are two key drivers moving this industry ahead. The capacity of these drugs to increase insulin secretion and suppress glucagon release leads not only to better blood sugar control but also to a better cardiovascular profile, putting them in a favorable position in the treatment of type 2 diabetes.
Furthermore, another important motivator is the emphasis on weight management, with several GLP-1 agonists demonstrating weight loss benefits. This is especially useful in managing the typical comorbidity of obesity and type 2 diabetes. These drugs' weight-loss effects make them an appealing alternative for both patients and healthcare practitioners. Additionally, the exploration of additional indications beyond diabetes, such as obesity and non-alcoholic fatty liver disease, represents a significant market expansion possibility. Non-diabetic applications research provides up new therapeutic paths, potentially increasing the spectrum of GLP-1 agonists.
Additionally, several trends are influencing market dynamics. For starters, the focus on cardiovascular outcomes trials (CVOTs) and the accompanying excellent results have elevated the profile of GLP-1 agonists, making them more appealing to healthcare practitioners looking for complete diabetes management. Second, the tendency toward producing oral preparations addresses a long-standing barrier: injection apprehension. If successfully produced, oral GLP-1 agonists could revolutionize the market by improving patient adherence.
Despite these encouraging trends, the market has hurdles, including due to the high cost of GLP-1 agonists, which may limit access for specific patient populations. This economic barrier, combined with injection-related concerns, may limit widespread usage. Finally, the GLP-1 agonists market is characterized by attractive drivers, prospects, and trends. While there are limitations, the promise of improved diabetes management, cardiovascular benefits, and new formulations places GLP-1 agonists at the forefront of diabetes care. The changing landscape emphasizes the importance of ongoing research, patient education, and smart market strategies to ensure the continued expansion and success of GLP-1 agonists in the dynamic field of diabetes treatments.
Study Period
2024-2030Base Year
2023CAGR
17.9%Largest Market
North AmericaFastest Growing Market
North America
The dynamics of the GLP-1 agonists market are impacted by a variety of factors, with once-weekly formulations being a particularly dominant category. This market has grown in popularity because of its capacity to address the long-standing issue of patient adherence. When compared to daily injections, the simplicity of a once-weekly dosing schedule dramatically improves patient compliance. This dominant segment is consistent with the overall pharmaceutical industry trend of improving patient experience and adherence.
The once-weekly formulations not only provide effective glucose control, but also help to make the treatment routine more patient-friendly. Because lower injection frequency can lead to enhanced patient satisfaction and better treatment outcomes, the once-weekly category has emerged as a major force in the GLP-1 agonists market. As a result, pharmaceutical companies are expanding their investments in the development and marketing of these formulations in order to profit from the enormous influence they have on patient convenience and adherence.
Semaglutide, Dulaglutide, Liraglutide, and Tirzepatide dominate the GLP-1 agonist market. Among all, Tirzepatide is projected to grow at a CAGR of 37% over the forecast period. Owing to its potential benefits in treating diabetes and off-label use for obese conditions, the molecule will bring cumulative sales of more than USD 100 billion by 2029. Eli Lilly is also aggressively spending on DTC TV ads to promote the sales of the molecule. The company has received approval of its Tirzepatide for diabetes and weight loss conditions in Europe and the USA.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2022 |
US$ 21,867.6 million |
Market CAGR |
17.9% |
By Route Of Administration |
|
By Molecule |
|
By Distribution Channel |
|
Download Free Sample Report
The GLP agonist market was valued at US$ 21,867.6 million in 2022 and is poised to grow at a CAGR of 17.9% over 2024-2030.
The focus on cardiovascular outcomes trials (CVOTs) and the accompanying excellent results have elevated the profile of GLP-1 agonists, making them more appealing to healthcare practitioners looking for complete diabetes management.
Eli Lilly and Company, and Novo Nordisk are key players in GLP-1 agonists market. Novo Nordisk generated more than US$ 20 billion in 2023 from its GLP-1 agonists drugs.
North America dominates the market with share of 73% CAGR in 2022, and is anticipated to grow with 17% CAGR over the forecast period 2023-2029.
1.Executive Summary |
2.Global GLP-1 Agonists Market Introduction |
2.1.Global GLP-1 Agonists Market - Taxonomy |
2.2.Global GLP-1 Agonists Market - Definitions |
2.2.1.By Route of Administration |
2.2.2.By Molecule |
2.2.3.By Distribution Channel |
2.2.4.By Region |
3.Global GLP-1 Agonists Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
4.Global GLP-1 Agonists Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global GLP-1 Agonists Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Oral |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Injection |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global GLP-1 Agonists Market By Molecule, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Dulaglutide |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Liraglutide |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Semaglutide |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Lixisenatide |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Exenatide |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Tirzepatide |
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
7.Global GLP-1 Agonists Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global GLP-1 Agonists Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. EMEA |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. RoW |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9.North America GLP-1 Agonists Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Oral |
9.1.2.Injection |
9.2. Molecule Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Dulaglutide |
9.2.2.Liraglutide |
9.2.3.Semaglutide |
9.2.4.Lixisenatide |
9.2.5.Exenatide |
9.2.6.Tirzepatide |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Others |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.EMEA GLP-1 Agonists Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Oral |
10.1.2.Injection |
10.2. Molecule Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Dulaglutide |
10.2.2.Liraglutide |
10.2.3.Semaglutide |
10.2.4.Lixisenatide |
10.2.5.Exenatide |
10.2.6.Tirzepatide |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Others |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.Spain |
10.4.5.UK |
10.4.6.Rest of EMEA |
11.RoW GLP-1 Agonists Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Route of Administration Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Oral |
11.1.2.Injection |
11.2. Molecule Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Dulaglutide |
11.2.2.Liraglutide |
11.2.3.Semaglutide |
11.2.4.Lixisenatide |
11.2.5.Exenatide |
11.2.6.Tirzepatide |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Others |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.Japan |
11.4.3.ANZ |
11.4.4.Brazil |
11.4.5.South Africa |
11.4.6.Rest of World |
12. Competition Landscape |
12.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
12.2.1. Eli Lilly and Company |
12.2.2. Sanofi |
12.2.3. AstraZeneca |
12.2.4. Novo Nordisk |
12.2.5. Twist Bioscience Corporation |
13. Research Methodology |
14. Appendix and Abbrevations |
List Of Table |
Table 01: Global GLP-1 Agonists Market- Historical, Forecast Market Share (USD Million), By Route of Administration, 2020-2029 |
Table 02: Global GLP-1 Agonists Market- Historical, Forecast Market Size (USD Million), By Molecule, 2020-2029 |
Table 03: Global GLP-1 Agonists Market- Historical, Forecast Market Size (USD Million), By Distribution Channel, 2020-2029 |
Table 04: Global GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Mn), By Region, 2020-2029 |
Table 05: North America GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Route of Administration, 2020-2029 |
Table 06: North America GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Molecule, 2020-2029 |
Table 07: North America GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Distribution Channel, 2020-2029 |
Table 08: North America GLP-1 Agonists Market - Historical, Forecast Market Size (USD Million), By Country, 2020-2029 |
Table 09: EMEA GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Route of Administration, 2020-2029 |
Table 10: EMEA GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Molecule, 2020-2029 |
Table 11: EMEA GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Distribution Channel, 2020-2029 |
Table 12: EMEA GLP-1 Agonists Market - Historical, Forecast Market Size (USD Million), By Country, 2020-2029 |
Table 13: RoW GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Route of Administration, 2020-2029 |
Table 14: RoW GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Molecule, 2020-2029 |
Table 15: RoW GLP-1 Agonists Market- Historical, Forecast Market Sizes (USD Million), By Distribution Channel, 2020-2029 |
Table 16: RoW GLP-1 Agonists Market - Historical, Forecast Market Size (USD Million), By Country, 2020-2029 |
List Of Figure |
Figure 01: Global GLP-1 Agonists Market Value (USD Million), 2020 - 2029 |
Figure 02: Overview of the Global GLP-1 Agonists Market Share (%), By Route of Administration, 2022 |
Figure 03: Overview of the Global GLP-1 Agonists Market value (USD Million), By Molecule, 2022 |
Figure 04: Overview of the Global GLP-1 Agonists Market value (USD Million), By Distribution Channel, 2022 |
Figure 05: Overview of the Global GLP-1 Agonists Market Value (Share %), By Region, 2022 |
Figure 06: Global GLP-1 Agonists Market Share (%) by Route of Administration, 2020, 2022 and 2029 |
Figure 07: Global GLP-1 Agonists Market Y-o-Y Growth (%), by Route of Administration, 2023-2029 |
Figure 08: Global GLP-1 Agonists Market, Historical, Forecast Market Size (USD Million) and Market Opportunity (USD Million), by Route of Administration, 2020, 2022, 2023 & 2029 |
Figure 09: Global GLP-1 Agonists Market Share (%) by Molecule, 2020, 2022 and 2029 |
Figure 10: Global GLP-1 Agonists Market Y-o-Y Growth (%), by Molecule, 2023-2029 |
Figure 11: Global GLP-1 Agonists Market, Historical, Forecast Market Size (USD Million) and Market Opportunity (USD Million), by Molecule, 2020, 2022, 2023 & 2029 |
Figure 12: Global GLP-1 Agonists Market Share (%) by Distribution Channel, 2020, 2022 and 2029 |
Figure 13: Global GLP-1 Agonists Market Y-o-Y Growth (%), by Distribution Channel, 2023-2029 |
Figure 14: Global GLP-1 Agonists Market, Historical, Forecast Market Size (USD Million) and Market Opportunity (USD Million), by Distribution Channel, 2020, 2022, 2023 & 2029 |
Figure 15: Global GLP-1 Agonists Market Share (%) by Region, 2020, 2022 and 2029 |
Figure 16: Global GLP-1 Agonists Market Y-o-Y Growth (%),by Region, 2023-2029 |
Figure 17: Global GLP-1 Agonists Market, Historical, Forecast Market Sizes (US$ Mn) and Market Opportunity (US$ Mn), by Region, 2020, 2022, 2023, & 2029 |
Figure 18: North America GLP-1 Agonists Market Shares Value (USD Million), 2020 - 2029 |
Figure 19: North America GLP-1 Agonists Market Shares (%), by Country - 2020, 2022, and 2029 |
Figure 20: North America GLP-1 Agonists Market Shares Y-o-Y Growth (%),by Country, 2023-2029 |
Figure 21: North America GLP-1 Agonists Market Shares (%), By Route of Administration, 2022 |
Figure 22: North America GLP-1 Agonists Market Shares (%), By Molecule, 2022 |
Figure 23: North America GLP-1 Agonists Market Shares (%), By Distribution Channel, 2022 |
Figure 24: EMEA GLP-1 Agonists Market Shares Value (USD Million), 2020 - 2029 |
Figure 25: EMEA GLP-1 Agonists Market Shares (%), by Country - 2020, 2022, and 2029 |
Figure 26: EMEA GLP-1 Agonists Market Shares Y-o-Y Growth (%),by Country, 2023-2029 |
Figure 27: EMEA GLP-1 Agonists Market Shares (%), By Route of Administration, 2022 |
Figure 28: EMEA GLP-1 Agonists Market Shares (%), By Molecule, 2022 |
Figure 29: EMEA GLP-1 Agonists Market Shares (%), By Distribution Channel, 2022 |
Figure 30: RoW GLP-1 Agonists Market Shares Value (USD Million), 2020 - 2029 |
Figure 31: RoW GLP-1 Agonists Market Shares (%), by Country - 2020, 2022, and 2029 |
Figure 32: RoW GLP-1 Agonists Market Shares Y-o-Y Growth (%),by Country, 2023-2029 |
Figure 33: RoW GLP-1 Agonists Market Shares (%), By Route of Administration, 2022 |
Figure 34: RoW GLP-1 Agonists Market Shares (%), By Molecule, 2022 |
Figure 35: RoW GLP-1 Agonists Market Shares (%), By Distribution Channel, 2022 |
Key Market Players